TNIK, a novel member of the germinal center kinase family that activates the c-Jun N-terminal kinase pathway and regulates the cytoskeleton

被引:157
|
作者
Fu, CA [1 ]
Shen, M [1 ]
Huang, BCB [1 ]
Lasaga, J [1 ]
Payan, DG [1 ]
Luo, Y [1 ]
机构
[1] Rigel Inc, S San Francisco, CA 94080 USA
关键词
D O I
10.1074/jbc.274.43.30729
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Germinal center kinases (GCKs) compose a subgroup of the Ste20 family of kinases. Here we describe the cloning and characterization of a novel GCK family kinase, Traf2- and Nck-interacting kinase (TNIK) that interacts with both Traf2 and Nck. TNIK encodes a polypeptide of 1360 amino acids with eight spliced isoforms. It has 90% amino acid identity to the Nck-interacting kinase in both the N-terminal kinase domain and the C-terminal germinal center kinase homology region. The homology drops to 53% in the intermediate region. TNIK specifically activates the c-Jun N-terminal kinase pathway when transfected into Phoenix-A cells (derivatives of 293 cells), similar to many GCKs. However, in contrast to other GCKs, this activation is mediated solely by the GCK homology region of TNIK. In addition, in Phoenix-A, NIH-3T3, and Hela cells, overexpression of wild type TNIK, but not the kinase mutant form of TNIK, results in the disruption of F-actin structure and the inhibition of cell spreading. Furthermore, TNIK can phosphorylate Gelsolin in vitro. This is the first time that a GCK family kinase is shown to be potentially involved in the regulation of cytoskeleton.
引用
收藏
页码:30729 / 30737
页数:9
相关论文
共 50 条
  • [21] Nitric oxide modulates the c-Jun N-terminal kinase stress-activated protein kinase activity through activating c-Jun N-terminal kinase kinase
    Kim, H
    Shim, J
    Han, PL
    Choi, EJ
    BIOCHEMISTRY, 1997, 36 (44) : 13677 - 13681
  • [22] c-Jun N-terminal kinase 2 suppresses pancreatic cancer growth and invasion and is opposed by c-Jun N-terminal kinase 1
    Tian, Xiaodong
    Traub, Benno
    Shi, Jingwei
    Huber, Nadine
    Schreiner, Stefan
    Chen, Guowei
    Zhou, Shaoxia
    Henne-Bruns, Doris
    Knippschild, Uwe
    Kornmann, Marko
    CANCER GENE THERAPY, 2022, 29 (01) : 73 - 86
  • [23] c-Jun N-terminal kinase 2 suppresses pancreatic cancer growth and invasion and is opposed by c-Jun N-terminal kinase 1
    Xiaodong Tian
    Benno Traub
    Jingwei Shi
    Nadine Huber
    Stefan Schreiner
    Guowei Chen
    Shaoxia Zhou
    Doris Henne-Bruns
    Uwe Knippschild
    Marko Kornmann
    Cancer Gene Therapy, 2022, 29 : 73 - 86
  • [24] The c-jun N-terminal kinase signaling pathway regulates airway smooth muscle cell proliferation
    Chiba, Sahoko
    Sumi, Yuki
    Okayasu, Kaori
    Okamoto, Tsukasa
    Tateishi, Tomoya
    Furusawa, Haruhiko
    Tsuchiya, Kimitake
    Fujie, Toshihide
    Tamaoka, Meiyo
    Sakashita, Hiroyuki
    Miyazaki, Yasunari
    Inase, Naohiko
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [25] Inhibition of the c-Jun N-terminal kinase (JNK) signaling pathway by curcumin
    Yi-Rong Chen
    Tse-Hua Tan
    Oncogene, 1998, 17 : 173 - 178
  • [26] The role of the c-Jun N-terminal Kinase signaling pathway in skin cancer
    Zhang, Jennifer Y.
    Selim, Maria Angelica
    AMERICAN JOURNAL OF CANCER RESEARCH, 2012, 2 (06): : 691 - 698
  • [27] Agents targeting c-Jun N-terminal kinase pathway as potential neuroprotectants
    Zhang, GY
    Zhang, QG
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2005, 14 (11) : 1373 - 1383
  • [28] Vincristine activates c-Jun N-terminal kinase in chronic lymphocytic leukemia in vivo
    Bates, Darcy J. P.
    Danilov, Alexey V.
    Beaulieu, Bernard B.
    Lewis, Lionel D.
    Eastman, Alan
    CANCER RESEARCH, 2013, 73 (08)
  • [29] Inhibition of the c-Jun N-terminal kinase (JNK) signaling pathway by curcumin
    Chen, YR
    Tan, TH
    ONCOGENE, 1998, 17 (02) : 173 - 178
  • [30] Vincristine activates c-Jun N-terminal kinase in chronic lymphocytic leukaemia in vivo
    Bates, Darcy J. P.
    Lewis, Lionel D.
    Eastman, Alan
    Danilov, Alexey V.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 80 (03) : 493 - 501